Phase II Trial of Nivolumab, a Anti-PD-1 Monoclonal Antibody, As a Novel Neoadjuvant Pre-surgical Therapy for Locally Advanced Oral Cavity Cancer Save

Date Added
January 24th, 2017
PRO Number
Pro00062193
Researcher
David Neskey

Silhouette
Keywords
Cancer/Head & Neck
Summary

This is for adults diagnosed with locally advanced oral cavity cancer.The purpose of this study is to look at the effectiveness of nivolumab in patients with oral cavity cancer that is amendable to surgery. Patients will have screening tests to determine eligibility. If eligible, subjects will have three to four doses of nivolumab prior to undergoing surgery. After surgery, subjects will enter a follow up period.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login